Table 4.
Treatment group | Age/sex | Reported cause of death | Study day |
---|---|---|---|
Basiliximab + belatacept HD + MMF | 57/M | Sepsis | 18 |
61/M | Myocardial infarction | 23 | |
49/M | Multiple system organ failure | 25 | |
56/M | Sepsis | 127 | |
Belatacept HD + MMF | 43/M | Sepsis | 24 |
37/M | Sepsis | 84 | |
62/F | Multiple system organ failure | 111 | |
47/M | Gastrointestinal bleed | 147 | |
62/F | Unknown | 274 | |
58/M | Unknown | 278 | |
51/M | PML | 322 | |
Belatacept LD + MMF | 65/M | Multiple system organ failure | 2 |
59/F | Colon perforation | 8 | |
48/M | Acute hepatic failure | 16 | |
63/F | Pulmonary failure | 21 | |
53/M | Sepsis | 65 | |
50/M | Gunshot injury | 117 | |
58/F | Multiple system organ failure | 202 | |
55/M | Multiple system organ failure | 208 | |
65/F | Multiple system organ failure | 339 | |
51/M | PTLD | 364 | |
Tacrolimus + MMF | 54/M | Sepsis | 168 |
Tacrolimus | 49/M | Myocardial infraction | 34 |
52/M | Multiple system organ failure | 63 | |
46/M | Gastrointestinal bleed | 68 | |
49/M | Sepsis | 286 |
F, female; HD, high dose, LD, low dose; M, male; MMF, mycophenolate mofetil; PML, progressive multifocal leukoencephalopathy; PTLD, posttransplant lymphoproliferative disease.